Betula Verrucosa — supply status, manufacturers & alternatives

Betula Verrucosa

—

In supply · Australia

Alutard SQ

In supply · 🇦🇺 Australia

In supply in Australia

No active shortage reported.

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Betula Verrucosa
Brand names	Alutard SQ
Therapeutic category	Auto-created by Lyfjastofnun — Tilkynntur lyfjaskortur (Iceland Medicines Agency) scraper
Controlled substance	No

Registrations on file	1

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🌐

IMA · 1h ago

Resolved

Verified timeline regulator events

🌐 24 Dec 2025

Shortage resolved

Sources official regulators

🌐

IMA

verified 1h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders1 registration · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
Soluprick Sq Betula Verrucosa	—	soluprick	🇬🇧 GB	ALK ABELLO A-S	Active

Mederti Drug Report

Generated 3 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.